RxDoctor Payments Data

Manolo Gallego, MD

Nephrology · Marietta, GANPI 1275520793

Payments from drug & device makers

$1,206in general payments, 2019–2025

Across 53 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$268
  • Fresenius USA Marketing, Inc.$184
  • Otsuka America Pharmaceutical, Inc.$112
  • Mallinckrodt Hospital Products Inc.$80
  • Vifor Pharma, Inc.$76
  • Akebia Therapeutics Inc$72
  • plus $413 from 13 others

What the payments were for

  • Food & beverage$1,14295%
  • Education$645%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,206 in reported general payments places this provider in the 40th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$244,106
Medicare patients
643
Services billed
2,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol19$29,515
Sevelamer Carbonate58$9,987
Cinacalcet Hcl13$4,514
Potassium Citrate ErPotassium Citrate31$4,122
Sodium Polystyrene Sulfonate49$3,849
Labetalol Hcl66$3,124
Tolvaptan11$2,610
Calcitriol146$2,599
Doxazosin Mesylate101$2,174
Potassium Chloride87$1,526
Hydralazine Hcl110$1,328
Colchicine20$1,144
Famotidine77$1,052
Losartan Potassium136$955
Febuxostat17$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$268$29,51519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 388 nephrology providers in Georgia.

Other nephrology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →